{"id":50490,"date":"2022-11-04T10:02:13","date_gmt":"2022-11-04T09:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/"},"modified":"2022-11-04T10:02:13","modified_gmt":"2022-11-04T09:02:13","slug":"future-planet-capital-backs-roslin-techs-momentum-with-further-investment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/","title":{"rendered":"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–Future Planet Capital<\/a> (\u201cFPC\u201d), the international venture capital and impact investor, is pleased to announce its participation in Edinburgh-based food & ag tech company Roslin Technologies<\/a>\u2019s latest \u00a311m funding round, helping to fuel the company\u2019s next wave of growth in its mission to become the leading provider of animal cell lines to the emerging cultivated meat sector.\n<\/p>\n

<\/a><\/p>\n

\nCultivated meat is meat grown directly from animal cells without the need to raise animals. Cultivated meat offers a promise to improve animal welfare, lower antibiotics use, and reduce the environmental footprint of meat production. The cultivated meat sector is rapidly growing with billions of dollars invested to date, in over 100 active companies including global meat producers. To make cultivated meat viable, production cost needs to come down and products need to create great consumer satisfaction. High quality cell lines are required to make cultivated meat safe, affordable and nutritious.\n<\/p>\n

\nHaving made an initial investment of \u00a310m in 2017, FPC has supported Roslin as it has grown from an intial concept to the revenue generating commercial enterprise it is today through board representation, funding and strategic commercial introductions. FPC was also honoured to facilitate an introduction to the now King Charles at its leadership event at COP 26. As a long term partner looking to profitably solve the world\u2019s greatest challenges, FPC is now pleased to be making a substantial contribution to this latest round via its Blue Ocean mandate and its Challenge Response II (CRII) strategy.\n<\/p>\n

\nThis new funding will allow Roslin Tech to invest in expanding its cell line portfolio and further developing the protocols for scale up of its cells into competitive cell biomass for meat production. It will do so jointly with its customers, development collaborators, and the University of Edinburgh with which Roslin Tech has a privileged relationship. It will also invest in its insect venture which focuses on breeding better insects for the emerging insect protein sector, a promising regenerative agricultural technique.\n<\/p>\n

\nGuy Pengelley, Investment Director at Future Planet Capital, said<\/b>: \u201cRoslin\u2019s ambitions to create disruptive biotechnologies to improve how proteins are made, very much aligns with FPC\u2019s mission to deliver returns while tackling the world\u2019s greatest challenges. As an early investor, we\u2019re delighted to be in the position to continue to back their both their momentum and continued growth and are excited to see what more we can achieve together over the longer term.\u201d<\/i>\n<\/p>\n

\nErnst van Orsouw, CEO of Roslin Tech, says:<\/b> \u201cThe closing of this series A round is a real milestone for Roslin Tech as we look to commercialise our ground-breaking stem cell technologies. The trust from the new investors is a testament to the platform and team that we have built with support from Future Planet Capital and our other founding shareholders. We are very pleased that Future Planet Capital continues to support us both financially and strategically. Their networks are incredibly valuable to continue to grow our business and have an impact on society\u201d.<\/i>\n<\/p>\n

\nENDS\n<\/p>\n

\nAbout Future Planet Capital<\/b>\n<\/p>\n

\nFuture Planet is the impact-led venture capital firm built to back growth companies from the world’s top universities and research ecosystems. Headquartered in London, but investing globally, the firm manages over $350M for institutional investors having backed over 180 companies across geographies and stages. Future Planet Capital\u2019s goal is to profitably solve the world’s greatest challenges in climate change, education, health, sustainable growth & security.\n<\/p>\n

\nBlue Ocean<\/b>\n<\/p>\n

\nThe Blue Ocean mandate aims for a portfolio of ten to fifteen high-growth and high-impact companies that profitably tackle key issues within the Blue Economy. The strategy is partnered with the Prince Albert II of Monaco Foundation and the Monaco Government in the context of the Monaco Blue Initiative (MBI).\n<\/p>\n

\nManaged by Future Planet Capital\u2019s experienced investment team, including Ed Phillips, Partner and Head of Origination, and Lyle Pentith, Portfolio Manager, the investment strategy focuses on three areas within the Blue Economy: preventing pollution, preservation of marine environments and ecosystems and sustainable marine productivity.\n<\/p>\n

\nChallenge Response II<\/b>\n<\/p>\n

\nFuture Planet Challenge Response II (CRII) is a thematic basket investing in top companies directly combating the effects of climate change. It is part of a wider series, providing preferred access to investment into growth-stage life science and technology companies from the world\u2019s top universities. It is designed to provide a rapid investment response to immediate global challenges.\n<\/p>\n

\nCRII, managed by Lyle Pentith, invests in three themes: Energy and Emissions, Sustainable Consumption, and Food Agriculture and the Environment.\n<\/p>\n

\nAbout Roslin Technologies Limited<\/b>\n<\/p>\n

\nBased outside Edinburgh, Roslin Technologies Limited is an ambitious food and agriculture technology company which creates disruptive biotechnologies to improve how proteins are made. The company\u2019s core capabilities lie in developing and commercialising a suite of unique animal stem cells and resources for the nascent global cultivated meat industry. Roslin Technologies was founded in 2017 as a venture between two investment firms and the University of Edinburgh with which it has an privileged relationship with certain rights to commercialise intellectual property from the University\u2019s school of veterinary medicine and the Roslin Institute, a global leader in animal science.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nH\/Advisors Maitland<\/b>
Jonathan Cook, Jonathan.cook@h-advisors.global<\/a>
Kate Pledger, kate.pledger@h-advisors.global<\/a>
T: 020 7379 5151\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–Future Planet Capital (\u201cFPC\u201d), the international venture capital and impact investor, is pleased to announce its participation in Edinburgh-based food & ag tech company Roslin Technologies\u2019s latest \u00a311m funding round, helping to fuel the company\u2019s next wave of growth in its mission to become the leading provider of animal cell lines to the emerging … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50490","6":"format-standard","7":"category-industry"},"yoast_head":"\nFuture Planet Capital backs Roslin Tech\u2019s momentum with further investment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–Future Planet Capital (\u201cFPC\u201d), the international venture capital and impact investor, is pleased to announce its participation in Edinburgh-based food & ag tech company Roslin Technologies\u2019s latest \u00a311m funding round, helping to fuel the company\u2019s next wave of growth in its mission to become the leading provider of animal cell lines to the emerging ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-04T09:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221103005785\/en\/1625334\/21\/logo_Future_Planet_Captial_%28002%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment\",\"datePublished\":\"2022-11-04T09:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/\"},\"wordCount\":882,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005785\\\/en\\\/1625334\\\/21\\\/logo_Future_Planet_Captial_%28002%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/\",\"name\":\"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005785\\\/en\\\/1625334\\\/21\\\/logo_Future_Planet_Captial_%28002%29.jpg\",\"datePublished\":\"2022-11-04T09:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005785\\\/en\\\/1625334\\\/21\\\/logo_Future_Planet_Captial_%28002%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005785\\\/en\\\/1625334\\\/21\\\/logo_Future_Planet_Captial_%28002%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/","og_locale":"en_US","og_type":"article","og_title":"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–Future Planet Capital (\u201cFPC\u201d), the international venture capital and impact investor, is pleased to announce its participation in Edinburgh-based food & ag tech company Roslin Technologies\u2019s latest \u00a311m funding round, helping to fuel the company\u2019s next wave of growth in its mission to become the leading provider of animal cell lines to the emerging ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-04T09:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221103005785\/en\/1625334\/21\/logo_Future_Planet_Captial_%28002%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment","datePublished":"2022-11-04T09:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/"},"wordCount":882,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103005785\/en\/1625334\/21\/logo_Future_Planet_Captial_%28002%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/","url":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/","name":"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103005785\/en\/1625334\/21\/logo_Future_Planet_Captial_%28002%29.jpg","datePublished":"2022-11-04T09:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221103005785\/en\/1625334\/21\/logo_Future_Planet_Captial_%28002%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221103005785\/en\/1625334\/21\/logo_Future_Planet_Captial_%28002%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/future-planet-capital-backs-roslin-techs-momentum-with-further-investment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Future Planet Capital backs Roslin Tech\u2019s momentum with further investment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50490"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50490\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}